Peers: GOSS IKT MIST CYTK CVKD TNYA MNKD KARD MLYS LXRX

| Held by: VTI IWM IWN VXF VTWO IWC FESM SBIO VTWV DFAC

Index	RUT
Market Cap	66.62M
Enterprise Value	-51.36M
Income	-64.86M
Sales	0.00M
Book/sh	3.56
Cash/sh	3.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	16
IPO	Apr 04, 1994

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.50
P/C	0.56
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	15.07
Current Ratio	15.07
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-1.47
EPS next Y	-1.45
EPS next Q	-0.36
EPS this Y	-8.54%
EPS next Y	0.53%
EPS next 5Y	-8.69%
EPS past 3/5Y	86.93% 77.09%
Sales past 3/5Y	- -
EPS Y/Y TTM	-59.74%
Sales Y/Y TTM	-
EPS Q/Q	-27.69%
Sales Q/Q	-
Earnings	Jul 31 BMO
EPS/Sales Surpr.	8.21% -

Insider Own	9.48%
Insider Trans	103.97%
Inst Own	94.27%
Inst Trans	27.90%
ROA	-57.02%
ROE	-59.80%
ROIC	-57.10%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.21%
SMA50	-3.52%
SMA200	-82.88%
Trades

Shs Outstand	37.42M
Shs Float	33.88M
Short Float	21.20%
Short Ratio	1.28
Short Interest	7.18M
52W High	19.40 -90.82%
52W Low	1.31 35.88%
Volatility	9.50% 6.68%
ATR (14)	0.16
RSI (14)	41.98
Beta	0.99
Rel Volume	0.05
Avg Volume	5.62M
Volume	15,315

Perf Week	30.88%
Perf Month	-5.82%
Perf Quarter	-89.01%
Perf Half Y	-87.55%
Perf YTD	-85.40%
Perf Year	-75.72%
Perf 3Y	-92.45%
Perf 5Y	-99.93%
Perf 10Y	-100.00%
Recom	1.80
Target Price	9.62
Prev Close	1.76
Price	1.78
Change %	1.14%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-31-26	Downgrade	Guggenheim	Buy → Neutral
Aug-11-26	Downgrade	Evercore ISI	Outperform → In-line	$5
Aug-11-26	Downgrade	Chardan Capital Markets	Buy → Neutral	$5
Jul-28-26	Initiated	Canaccord Genuity	Buy	$35
Jul-22-26	Initiated	Evercore ISI	Outperform	$39
Jun-22-26	Initiated	Chardan Capital Markets	Buy	$27
Mar-17-26	Initiated	Cantor Fitzgerald	Overweight	$35
Sep-08-25	Initiated	Piper Sandler	Overweight	$20
Oct-24-24	Initiated	Leerink Partners	Outperform	$16
Oct-14-24	Initiated	Guggenheim	Buy	$16
Sep-30-24	Initiated	William Blair	Outperform
May-18-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-16-14	Initiated	MLV & Co	Buy	$7
Nov-18-14	Initiated	WallachBeth	Buy	$12

Show Previous Ratings

Sep-01-26 07:00AM	Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference (GlobeNewswire)
Aug-31-26 09:45AM	Deere upgraded, Lumentum initiated: Wall Street's top analyst calls (The Fly) -13.62%
Aug-29-26 08:21AM	Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 (GlobeNewswire)
Aug-11-26 07:15AM	Tenax Therapeutics stock crashes on Phase III trial failure (Clinical Trials Arena) +17.82%
Aug-10-26 11:03AM	Tenax Therapeutics Phase 3 LEVEL Trial Misses Primary Endpoint for TNX-103 (InvestorsHub) -89.77%
10:52AM	Loading…
10:52AM	Tenax, Sionna Shares Sink After Trial Failures (The Wall Street Journal)
10:23AM	Why Did TENX Stock Crash 89% Today? (Stocktwits)
08:25AM	Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout (Investing.com)
07:00AM	Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF (GlobeNewswire)
Jul-31-26 07:08AM	Tenax Therapeutics: Q2 Earnings Snapshot (Associated Press) -9.27%
07:00AM	Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-02-26 04:05PM	Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +16.33% +5.17%
08:48AM	Three Years of War Changed What Governments Buy. One Player is Already Winning Contracts (NASDAQ: MDWD) (FinanceWire)
07:00AM	Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 (GlobeNewswire)
May-12-26 07:07AM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press)
07:00AM	Loading…
07:00AM	Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-26 04:05PM	Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-04-26 07:00AM	Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer (GlobeNewswire)
Apr-22-26 07:00AM	Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer (GlobeNewswire)
Mar-17-26 09:33AM	DraftKings, Eli Lilly downgraded: Wall Street's top analyst calls (The Fly) +8.51%
Mar-10-26 07:24AM	Tenax Therapeutics: Q4 Earnings Snapshot (Associated Press Finance) +31.67%
07:00AM	Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-03-26 07:00AM	Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference (GlobeNewswire)
Feb-15-26 01:03PM	Tenax Therapeutics Shares Phase III Levosimendan Progress, H2 Data Timeline at Guggenheim Conference (MarketBeat)
Feb-04-26 07:00AM	Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 (GlobeNewswire)
Jan-08-26 02:00PM	Guggenheim Doubles Tenax (TENX) PT, Names Stock Top Pick (Insider Monkey)
Dec-17-25 09:16AM	Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment (GlobeNewswire) +5.65%
Nov-25-25 07:00AM	Tenax Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-25 04:17PM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Loading…
Nov-06-25 07:00AM	Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF (GlobeNewswire)
Nov-03-25 07:00AM	Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Sep-16-25 07:00AM	Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF (GlobeNewswire)
Aug-28-25 07:00AM	Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025 (GlobeNewswire)
Aug-13-25 04:17PM	Tenax Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-14-25 04:38PM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-16-25 04:29PM	Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts (Seeking Alpha)
Mar-31-25 08:00AM	Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-25-25 04:25PM	Tenax Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-25 08:47AM	Tenax Therapeutics Announces $25 Million Private Placement (GlobeNewswire)
08:42AM	Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF (GlobeNewswire)
Mar-03-25 08:00AM	Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference (GlobeNewswire)
Jan-31-25 09:00AM	Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Jan-22-25 08:00AM	Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations (GlobeNewswire)
Nov-13-24 07:19AM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-04-24 07:30AM	Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors (PR Newswire)
Oct-31-24 04:05PM	Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference (GlobeNewswire)
Aug-13-24 04:37PM	Tenax Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.63%
04:05PM	Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-12-24 08:00AM	Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program (GlobeNewswire) -10.86%
Aug-06-24 07:13AM	Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement (GlobeNewswire) +28.77%
May-14-24 01:53PM	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:10AM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-30-24 07:30AM	Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +6.27%
Apr-09-24 08:30AM	Tenax Therapeutics to Host KOL Event: LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study (GlobeNewswire)
Mar-28-24 09:54PM	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +9.56% -9.91%
08:30AM	Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results (GlobeNewswire)
Mar-12-24 08:30AM	Tenax Therapeutics to Present at the 36th Annual Roth Conference (GlobeNewswire)
Feb-29-24 09:00AM	Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 (GlobeNewswire) +10.87%
Feb-20-24 08:30AM	Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan (GlobeNewswire)
Feb-08-24 08:53AM	Why Is Tenax Therapeutics (TENX) Stock Down 64% Today? (InvestorPlace) -64.45%
08:16AM	Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering (GlobeNewswire)
Feb-07-24 08:01PM	Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +24.54%
Feb-06-24 08:30AM	Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +31.31%
Dec-29-23 08:30AM	Tenax Therapeutics Announces Reverse Stock Split (GlobeNewswire) -16.79%
Nov-17-23 08:30AM	Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board (GlobeNewswire) -9.21%
Nov-14-23 05:05AM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -18.55%
Nov-13-23 03:22PM	Why Is Tenax Therapeutics (TENX) Stock Up 300% Today? (InvestorPlace) +297.44%
08:30AM	Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023 (GlobeNewswire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks) -5.96%
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace)
Jul-19-23 08:30AM	Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +10.40%
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research) +9.19%
May-31-23 08:54AM	Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +13.31%
May-22-23 06:44AM	TENX: Prioritizing Levosimendan (Zacks Small Cap Research) +5.71%
Apr-21-23 03:59PM	10 Stocks Targeted By Short Sellers Recently (Insider Monkey)
Apr-12-23 02:50PM	Tenax Therapeutics Prioritizes Development Of TNX-103 For Heart Failure (Benzinga)
08:45AM	Tenax Therapeutics Provides 2023 Business Update (GlobeNewswire)
Apr-05-23 05:49AM	TENX: Patents Guide the Way (Zacks Small Cap Research) -7.89%
Mar-22-23 08:45AM	Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) -5.36%
Feb-17-23 07:05AM	Analysts Are Optimistic We'll See A Profit From Tenax Therapeutics, Inc. (NASDAQ:TENX) (Simply Wall St.)
Feb-15-23 08:05AM	TENX: New Funding Puts Wind in the Sails (Zacks Small Cap Research)
Feb-07-23 12:10PM	Triangle pharma raising millions amid uncertain future (American City Business Journals) -8.02%
Feb-03-23 08:19AM	Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering (GlobeNewswire) -20.81%
Feb-02-23 10:43AM	Why Tenax Therapeutics Shares Are Gaining Today? (Benzinga) +30.77%
Feb-01-23 04:31PM	Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) -20.28%
Jan-04-23 08:00AM	Tenax Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Nov-03-22 07:16AM	TENX: Agility Required to Unlock Considerable Upside (Zacks Small Cap Research) -20.03%
Oct-10-22 08:30AM	Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire)
Sep-15-22 09:29AM	Tenax Therapeutics Stock Jumps On Strategic Alternative Review (Benzinga) +11.25%
08:30AM	Tenax Therapeutics Announces the Evaluation of Strategic Alternatives (GlobeNewswire)
Aug-28-22 09:23AM	Loss-Making Tenax Therapeutics, Inc. (NASDAQ:TENX) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Aug-23-22 05:58AM	TENX: The Pressures On: Awaiting Phase 3 Start (Zacks Small Cap Research)
Jul-01-22 07:52AM	Chapel Hill company given extension to regain Nasdaq compliance (American City Business Journals) +6.07%
May-25-22 08:30AM	Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH) (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADAR1 Capital Management, LLC	10% Owner	Oct 21 '26	Buy	1.66	331,979	550,687	7,447,000	Oct 21 04:49 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 19 '26	Buy	1.51	336,528	507,013	6,860,679	Oct 21 04:49 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 20 '26	Buy	1.60	254,342	405,726	7,115,021	Oct 21 04:49 PM
Doogan Declan	Director	Sep 16 '26	Buy	1.92	53,000	101,760	55,274	Sep 17 09:30 PM
Giordano Christopher Thomas	CEO	Sep 11 '26	Buy	1.88	6,000	11,250	17,324	Sep 15 09:38 PM
Giordano Christopher Thomas	CEO	Sep 15 '26	Buy	1.82	4,850	8,837	22,174	Sep 15 09:38 PM
STAAB THOMAS R II	Chief Financial Officer	Sep 11 '26	Buy	1.94	5,675	10,981	15,675	Sep 15 09:30 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 03 '26	Buy	1.78	900,000	1,604,160	6,524,151	Sep 08 05:16 PM
ADAR1 Capital Management, LLC	10% Owner	Aug 31 '26	Buy	1.79	403,571	722,594	5,257,389	Sep 02 05:52 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 02 '26	Buy	1.80	187,704	337,586	5,624,151	Sep 02 05:52 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 01 '26	Buy	1.80	179,058	321,570	5,436,447	Sep 02 05:52 PM
ADAR1 Capital Management, LLC	10% Owner	Aug 21 '26	Buy	1.77	716,369	1,266,254	4,746,444	Aug 24 06:12 PM
ADAR1 Capital Management, LLC	10% Owner	Aug 20 '26	Buy	1.78	202,124	359,538	4,030,075	Aug 24 06:12 PM
ADAR1 Capital Management, LLC	10% Owner	Aug 24 '26	Buy	1.75	107,374	188,355	4,853,818	Aug 24 06:12 PM
Giordano Christopher Thomas	CEO	Jul 13 '26	Option Exercise	5.88	8,719	51,267	11,324	Jul 14 07:29 PM
Rich Stuart	Chief Medical Officer	Dec 09 '25	Buy	10.22	2,500	25,542	5,266	Dec 10 06:48 PM
Rich Stuart	Chief Medical Officer	Dec 08 '25	Buy	10.10	2,500	25,250	5,000	Dec 10 06:48 PM
Rich Stuart	Chief Medical Officer	Dec 04 '25	Buy	9.20	2,500	22,998	2,500	Dec 05 05:46 PM
Rich Stuart	Chief Medical Officer	Dec 03 '25	Buy	9.08	1,500	13,618	2,766	Dec 05 05:46 PM
Rich Stuart	Chief Medical Officer	Dec 02 '25	Buy	9.01	1,000	9,006	1,266	Dec 05 05:46 PM
Giordano Christopher Thomas	CEO	Nov 18 '25	Buy	7.75	1,612	12,500	1,612	Nov 20 06:38 PM
Giordano Christopher Thomas	CEO	Nov 20 '25	Buy	7.59	538	4,083	2,605	Nov 20 06:38 PM
Giordano Christopher Thomas	CEO	Nov 19 '25	Buy	7.51	455	3,417	2,067	Nov 20 06:38 PM
MCGAULEY THOMAS	Interim CFO	Nov 17 '25	Buy	7.25	6,000	43,490	5,000	Nov 19 07:01 PM
MCGAULEY THOMAS	Interim CFO	Nov 17 '25	Buy	7.34	2,000	14,674	2,000	Nov 19 07:01 PM
Almenoff June Sherie	Director	Nov 18 '25	Buy	7.52	1,900	14,280	1,993	Nov 19 06:43 PM
Almenoff June Sherie	Director	Nov 17 '25	Buy	7.15	93	665	93	Nov 19 06:43 PM

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

CEOMr. Christopher T. Giordano

Principal Financial Officer & Principal Accounting OfficerMr. Thomas A. McGauley

Chief Medical Officer & DirectorDr. Stuart Rich M.D.

CPAMr. Thomas R. Staab II

Chief Business OfficerMr. Doug Randall

INM InMed Pharmaceuticals Inc daily Stock Chart

Peers: IXHL CRDL OPTH SUPN ARTL BIVI AXSM AVXL TNXP EYPT

Index	-
Market Cap	7.04M
Enterprise Value	4.81M
Income	-12.99M
Sales	1.94M
Book/sh	0.20
Cash/sh	0.41
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Nov 17, 2008

P/E	-
Forward P/E	-
PEG	-
P/S	3.63
P/B	6.36
P/C	3.15
P/FCF	-
EV/EBITDA	-
EV/Sales	2.48
Quick Ratio	1.37
Current Ratio	1.37
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-3.12
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	63.64% 66.67%
Sales past 3/5Y	- -
EPS Y/Y TTM	66.05%
Sales Y/Y TTM	-60.74%
EPS Q/Q	-60.54%
Sales Q/Q	-100.00%
Earnings	Sep 09 AMC
EPS/Sales Surpr.	- -

Insider Own	15.57%
Insider Trans	105.41%
Inst Own	36.84%
Inst Trans	106.94%
ROA	-122.41%
ROE	-157.00%
ROIC	-1168.44%
Gross Margin	-6.30%
Oper. Margin	-510.84%
Profit Margin	-669.61%
SMA20	-4.41%
SMA50	-6.43%
SMA200	7.46%
Trades

Shs Outstand	5.34M
Shs Float	4.64M
Short Float	0.73%
Short Ratio	0.34
Short Interest	0.03M
52W High	2.33 -45.06%
52W Low	0.57 122.61%
Volatility	3.83% 3.71%
ATR (14)	0.06
RSI (14)	39.17
Beta	0.98
Rel Volume	0.05
Avg Volume	100.17K
Volume	230

Perf Week	-3.03%
Perf Month	-8.57%
Perf Quarter	-21.95%
Perf Half Y	65.93%
Perf YTD	20.75%
Perf Year	-36.95%
Perf 3Y	-88.97%
Perf 5Y	-99.84%
Perf 10Y	-99.94%
Recom	1.00
Target Price	468.78
Prev Close	1.33
Price	1.28
Change %	-3.76%

Oct-14-26 09:47PM	How Much Downside Is Left In Liquidia Stock? (Trefis)
Sep-18-26 04:45PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Shareholders' Equity Compliance (Newsfile)
Sep-09-26 04:30PM	InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update (Newsfile)
Jul-22-26 07:00AM	Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline (PR Newswire) +7.79%
Jul-06-26 07:15PM	Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders? (PR Newswire)
06:20PM	Loading…
06:20PM	InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4 (Newsfile)
Jun-12-26 11:51AM	Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-04-26 05:00PM	InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements (Newsfile)
May-28-26 06:57PM	Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders? (PR Newswire) -6.55%
May-19-26 10:37AM	InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM) (InvestorsHub) +135.05%
08:00AM	InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies (PR Newswire)
07:19AM	A migraine drugmaker heads to the public markets through reverse merger (BioPharma Dive)
06:00AM	InMed Pharmaceuticals Amends Preferred Investment Options (Newsfile Corp.)
May-06-26 06:00PM	InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile)
Apr-27-26 05:30PM	InMed Pharmaceuticals Amends Preferred Investment Options (Newsfile) -5.03%
05:05PM	Loading…
Mar-27-26 05:05PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance (Newsfile) -6.22%
Mar-23-26 07:30AM	InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program (Newsfile) -6.92%
Mar-18-26 08:00AM	Sidoti Events, LLC's March Small-Cap Virtual Conference (ACCESSWIRE)
Mar-09-26 07:30AM	InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial (Newsfile)
Mar-06-26 05:04PM	InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline (Newsfile)
Feb-11-26 05:23PM	InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile) -10.09%
Dec-17-25 08:00PM	InMed Announces Results of 2025 Annual General and Special Meeting (Newsfile) -8.75% +7.50%
Dec-12-25 05:30PM	InMed Provides Update on BayMedica Commercial Business (Newsfile) -16.08%
Nov-18-25 07:30AM	InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901 (Newsfile) -11.52%
Nov-06-25 04:51PM	InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update (Newsfile) -6.16%
Oct-16-25 08:30AM	InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors (Newsfile) -5.45%
Oct-09-25 08:30AM	InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors (Newsfile)
Sep-24-25 08:45AM	InMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last year (TipRanks)
Sep-23-25 08:30AM	InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update (Newsfile) -5.73%
Sep-05-25 01:33PM	InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (Newsfile)
07:00AM	Loading…
Jul-28-25 07:00AM	InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 (Newsfile)
Jun-27-25 07:00AM	InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules (Newsfile)
Jun-25-25 08:00AM	InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules (Newsfile)
Jun-24-25 07:00AM	InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study (Newsfile) +57.96%
Jun-13-25 04:30PM	InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA (Newsfile) -5.95% -6.32%
May-12-25 06:00PM	InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile) +14.91%
Feb-12-25 06:54PM	InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile)
Feb-03-25 07:30AM	InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration (Newsfile)
Jan-22-25 07:30AM	InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds (Newsfile) -20.79%
Jan-21-25 07:30AM	InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study (Newsfile)
Dec-18-24 08:00PM	InMed Announces Results of 2024 Annual General Meeting (Newsfile) -16.18%
Dec-17-24 04:56PM	InMed Enters Into Standby Equity Purchase Agreement (Newsfile)
Nov-19-24 07:30AM	InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System (Newsfile)
Nov-14-24 04:45PM	InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update (Newsfile) +9.29% -15.73%
Nov-08-24 04:44PM	InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules (Newsfile)
Nov-05-24 08:30AM	InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules (Newsfile) -7.41%
Oct-28-24 07:30AM	InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease (Newsfile) +6.63%
Oct-24-24 08:00AM	InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease (Newsfile)
Oct-22-24 08:00AM	InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board (Newsfile) +10.00%
Sep-30-24 08:00AM	InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Sep-20-24 04:30PM	InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date (Newsfile) -12.16%
Aug-21-24 07:30AM	InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents (Newsfile)
Aug-20-24 07:30AM	InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease (Newsfile) +191.35%
Jul-30-24 08:00AM	InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data (Newsfile) -17.59%
Jun-28-24 06:00AM	7 F-Rated Growth Stocks to Avoid Right Now: June 2024 (InvestorPlace)
Jun-12-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire)
Jun-11-24 07:00AM	Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now (GlobeNewswire)
Jun-10-24 05:18PM	InMed to Present at the Emerging Growth Conference (Newsfile)
Jun-06-24 07:38AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -15.51%
May-14-24 10:53PM	INM Stock Earnings: InMed Pharmaceuticals Reported Results for Q3 2024 (InvestorPlace)
08:30AM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Apr-18-24 08:00AM	InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board (Newsfile)
Apr-16-24 08:00AM	InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration (Newsfile)
Apr-04-24 08:00AM	InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies (Newsfile)
Mar-20-24 08:30AM	InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance (Newsfile)
Feb-13-24 05:41PM	InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update (Newsfile)
Feb-09-24 08:00AM	InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer (Newsfile)
Jan-18-24 04:41PM	InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET (Newsfile)
Jan-16-24 08:00AM	InMed Pharmaceuticals Provides Business Update and Milestones for 2024 (Newsfile)
Dec-19-23 06:03PM	InMed Announces Results of 2023 Annual General Meeting (Newsfile) +5.54%
Nov-29-23 08:00AM	InMed Expands its Pharmaceutical Pipeline with INM-089 targeting the treatment of Age-Related Macular Degeneration (Newsfile) +21.74%
Nov-14-23 08:04AM	InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update (Newsfile)
Nov-02-23 08:00AM	InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023 (Newsfile)
Oct-26-23 07:15PM	InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules (Newsfile) -9.53% -15.93%
Oct-25-23 09:00AM	Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today? (InvestorPlace) -24.18%
Oct-24-23 04:38PM	InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules (Newsfile) +70.53%
07:30AM	InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies (Newsfile)
Sep-29-23 01:21PM	InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update (Newsfile)
Sep-22-23 06:15PM	InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance (Newsfile)
Sep-07-23 08:30AM	InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference (Newsfile)
Jul-21-23 07:30AM	InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET (Newsfile) +6.05%
Jul-20-23 07:30AM	InMed Provides Update on BayMedica Rare Cannabinoid Business (Newsfile) +5.32%
Jun-22-23 02:28PM	Why Are InMed Pharmaceuticals Stock Trading Lower Today (Benzinga) -13.57%
07:30AM	InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa (Newsfile)
Jun-01-23 07:30AM	InMed's Neurodegenerative Disease Study Presented at Canadian Neuroscience Meeting (Newsfile)
May-24-23 06:51PM	InMed to Participate in Upcoming Virtual Investor Events (Newsfile)
May-18-23 05:00PM	InMed to Participate in Fireside Chat with Water Tower Research on May 23, 2023 at 1pm ET (Newsfile) +20.87%
May-15-23 12:33PM	InMed Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update (Newsfile)
Mar-28-23 07:30AM	InMed Announces Conclusion of Patient Enrollment in Phase 2 Clinical Trial Investigating INM-755 Cannabinol Cream for Epidermolysis Bullosa (Newsfile) -9.45%
Mar-13-23 07:30AM	InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions (Newsfile) +7.62%
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)
07:00AM	Presenting on the Emerging Growth Conference on March 8 Register Now (GlobeNewswire)
Mar-06-23 06:00PM	InMed to Participate in Upcoming Investor Events (Newsfile) +9.82%
Feb-17-23 05:00PM	InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.50%
Feb-09-23 09:41PM	InMed Submits Form 12b-25 (GlobeNewswire)
Jan-10-23 07:30AM	InMed Provides Business Update and Milestones for 2023 (GlobeNewswire) +36.09%
Dec-15-22 06:17PM	InMed Announces Results of 2022 Annual General Meeting (GlobeNewswire) -7.00%
Dec-12-22 06:47PM	InMed Announces Appointment of Interim Chief Financial Officer and Change of Auditor (GlobeNewswire)
Nov-23-22 12:18PM	Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory Update (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ADAR1 Capital Management, LLC	10% Owner	Oct 19 '26	Buy	1.32	1,086	1,434	956,580	Oct 20 05:31 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 16 '26	Buy	1.32	1	1	955,494	Oct 20 05:31 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 14 '26	Buy	1.33	8,021	10,668	954,509	Oct 15 04:39 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 15 '26	Buy	1.32	984	1,301	955,493	Oct 15 04:39 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 13 '26	Buy	1.33	564	750	946,488	Oct 15 04:39 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 06 '26	Buy	1.33	5,601	7,436	940,622	Oct 08 06:27 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 07 '26	Buy	1.33	3,046	4,051	943,668	Oct 08 06:27 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 08 '26	Buy	1.33	2,256	2,997	945,924	Oct 08 06:27 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 05 '26	Buy	1.33	18,182	24,182	935,021	Oct 05 05:11 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 01 '26	Buy	1.33	16,431	21,850	908,532	Oct 05 05:11 PM
ADAR1 Capital Management, LLC	10% Owner	Oct 02 '26	Buy	1.33	8,307	11,048	916,839	Oct 05 05:11 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 15 '26	Buy	1.30	54,256	70,446	883,761	Sep 16 06:58 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 14 '26	Buy	1.29	28,505	36,880	829,505	Sep 16 06:58 PM
ADAR1 Capital Management, LLC	10% Owner	Sep 16 '26	Buy	1.29	8,340	10,750	892,101	Sep 16 06:58 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 15 '26	Buy	1.55	1,000	1,555	801,000	Jul 17 07:29 PM
Vivo Opportunity, LLC	10% Owner	Jul 15 '26	Buy	1.55	15,150	23,482	743,038	Jul 16 09:58 PM
Vivo Opportunity, LLC	10% Owner	Jul 14 '26	Buy	1.55	5,375	8,331	729,277	Jul 16 09:58 PM
Vivo Opportunity, LLC	10% Owner	Jul 16 '26	Buy	1.55	21	33	743,057	Jul 16 09:58 PM
Vivo Opportunity, LLC	10% Owner	Jul 01 '26	Buy	1.55	4,344	6,733	722,935	Jul 02 07:02 PM
Vivo Opportunity, LLC	10% Owner	Jul 02 '26	Buy	1.55	1,607	2,491	724,395	Jul 02 07:02 PM
Vivo Opportunity, LLC	10% Owner	Jun 30 '26	Buy	1.54	600	924	718,989	Jul 02 07:02 PM
Vivo Opportunity, LLC	10% Owner	May 20 '26	Buy	1.56	56,210	87,688	543,129	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 05 '26	Buy	1.57	55,011	86,367	688,926	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	May 21 '26	Buy	1.69	34,000	57,460	574,011	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 08 '26	Buy	1.52	32,500	49,400	718,444	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 02 '26	Buy	1.52	22,848	34,729	625,766	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	May 29 '26	Buy	1.57	17,796	27,940	590,175	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 01 '26	Buy	1.55	16,336	25,321	605,013	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 03 '26	Buy	1.55	7,783	12,064	632,835	Jun 10 09:14 PM
Vivo Opportunity, LLC	10% Owner	Jun 04 '26	Buy	1.57	6,743	10,587	638,960	Jun 10 09:14 PM
ADAR1 Capital Management, LLC	10% Owner	May 19 '26	Buy	1.54	468,551	721,548	800,000	May 21 05:08 PM

InMed Pharmaceuticals, Inc. is a pharmaceutical drug development company, which engages in developing small molecule drug candidates that are preferential signaling ligands of the endogenous CB1 and CB2 receptors as well as other receptor targets linked to human disease. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

M.I.B.Mr. Eric A. Adams B.S. Chem.

CFO & Corporate SecretaryMs. N. Netta Jagpal

Chief Operating OfficerMr. Michael Woudenberg P.Eng.

Senior Vice President of Preclinical Research & DevelopmentDr. Eric Chih-Hsien Hsu Ph.D.

Ph.D.Dr. Sazzad Hossain M.Sc.

Open in Screener

NXTC

Nextcure Inc

4.60

Oct 23 • 4:04 AM ET -0.12 (-2.54%)

Healthcare Biotechnology USA Nano NASD

Peers: PYXS KYNB STRO MGNX CTMX BOLT ALXO ZYME HOWL CMPX

| Held by: VTI VXF IWC DFMC DFAC

Index	-
Market Cap	21.06M
Enterprise Value	5.26M
Income	-42.75M
Sales	0.00M
Book/sh	2.99
Cash/sh	4.39
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	40
IPO	May 09, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.54
P/C	1.05
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.47
Current Ratio	3.47
Debt/Eq	0.35
LT Debt/Eq	0.30
Option/Short	No / Yes

EPS (ttm)	-10.59
EPS next Y	-1.38
EPS next Q	-0.90
EPS this Y	67.74%
EPS next Y	78.23%
EPS next 5Y	60.40%
EPS past 3/5Y	15.29% -4.25%
Sales past 3/5Y	- -
EPS Y/Y TTM	59.14%
Sales Y/Y TTM	-
EPS Q/Q	75.16%
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-43.59% -

Insider Own	16.30%
Insider Trans	73.76%
Inst Own	47.86%
Inst Trans	-14.74%
ROA	-121.60%
ROE	-195.22%
ROIC	-271.38%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-19.79%
SMA50	-25.81%
SMA200	-42.70%
Trades

Shs Outstand	4.07M
Shs Float	3.83M
Short Float	5.57%
Short Ratio	1.11
Short Interest	0.21M
52W High	15.74 -70.77%
52W Low	1.55 196.77%
Volatility	16.92% 13.52%
ATR (14)	0.77
RSI (14)	36.92
Beta	1.28
Rel Volume	0.03
Avg Volume	192.73K
Volume	245

Perf Week	-26.28%
Perf Month	-12.88%
Perf Quarter	-10.16%
Perf Half Y	-56.27%
Perf YTD	-67.58%
Perf Year	-48.26%
Perf 3Y	-69.33%
Perf 5Y	-95.36%
Perf 10Y	-
Recom	1.00
Target Price	20.00
Prev Close	4.72
Price	4.60
Change %	-2.54%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-25	Upgrade	Ladenburg Thalmann	Neutral → Buy	$18
Nov-04-22	Downgrade	Ladenburg Thalmann	Buy → Neutral
Mar-01-22	Initiated	Ladenburg Thalmann	Buy	$16
Mar-05-21	Upgrade	Truist	Hold → Buy	$19
Jan-15-21	Downgrade	BofA Securities	Neutral → Underperform	$10
Jul-16-20	Upgrade	The Benchmark Company	Hold → Buy	$17
Jul-13-20	Downgrade	SunTrust	Buy → Hold
Jul-13-20	Downgrade	ROTH Capital	Buy → Neutral
Jun-01-20	Downgrade	The Benchmark Company	Buy → Hold
Jun-01-20	Downgrade	BofA/Merrill	Buy → Neutral	$62 → $40
May-26-20	Initiated	JMP Securities	Mkt Outperform	$55
Mar-24-20	Initiated	The Benchmark Company	Buy	$55
Mar-02-20	Initiated	ROTH Capital	Buy	$80
Jan-13-20	Initiated	SunTrust	Buy	$78
Dec-05-19	Initiated	Needham	Buy
Nov-26-19	Initiated	BTIG Research	Buy	$61
Jul-09-19	Initiated	BofA/Merrill	Buy	$25
Jun-03-19	Initiated	Piper Jaffray	Overweight	$26
Jun-03-19	Initiated	Morgan Stanley	Overweight	$25

Show Previous Ratings

Aug-06-26 04:01PM	NextCure Provides Business Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire) +6.48%
Jul-24-26 04:38PM	Halper Sadeh LLC is Investigating Whether VEEE, NXTC, TCBK, FHB are Obtaining Fair Deals for their Shareholders (PR Newswire) +20.75%
Jul-21-26 02:51PM	Are CRNX, VEEE, NXTC, TCBK Obtaining Fair Deals for their Shareholders? (PR Newswire) -5.37%
Jul-14-26 08:30AM	Surgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change That (FinanceWire) +201.83%
08:00AM	Fresh off buyout, Akero execs reunite to advance long-acting psoriasis pill (BioPharma Dive)
06:00AM	Loading…
06:00AM	NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy (GlobeNewswire)
Jun-04-26 08:00AM	NXTC Announces Replay Available for Virtual KOL Event Discussing ASCO 2026 Dose Escalation Data from Phase 1 Trial of SIM0505 for Gynecologic Cancers (GlobeNewswire)
Jun-01-26 08:00AM	NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026 (GlobeNewswire) -45.48%
May-07-26 04:05PM	NextCure Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire) -5.04%
May-04-26 07:05AM	NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers (GlobeNewswire)
Apr-21-26 10:15AM	NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026 (GlobeNewswire) -6.24%
Apr-07-26 08:05AM	NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer (GlobeNewswire)
Mar-31-26 04:05PM	NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 (GlobeNewswire) +7.88%
Mar-05-26 04:05PM	NextCure Provides Business Update and Reports Full Year 2025 Financial Results (GlobeNewswire)
Jan-23-26 07:00AM	NextCure Provides Business Update (GlobeNewswire) -5.77%
08:00AM	Loading…
Nov-20-25 08:00AM	NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-17-25 08:00AM	NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts (GlobeNewswire)
Nov-12-25 08:00AM	NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules (GlobeNewswire) +9.04%
Nov-11-25 09:55AM	Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect? (Zacks)
Nov-05-25 04:05PM	NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-16-25 08:05AM	NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States (GlobeNewswire) +27.75%
Sep-04-25 07:00AM	NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-07-25 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-24-25 04:05PM	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Improves Bone Microarchitecture and Reduces Fracture Incidence in Mice with Moderate-to-Severe Osteogenesis Imperfecta (GlobeNewswire) +17.30%
Jun-17-25 05:34AM	NextCure and Simcere partner to develop SIM0505 for solid tumours (Pharmaceutical Technology) -10.08%
Jun-16-25 07:05AM	NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6 (GlobeNewswire) -26.27%
May-29-25 11:03PM	NextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024 (Insider Monkey) +6.41%
04:05PM	NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025 (GlobeNewswire)
May-01-25 04:05PM	NextCure Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire) -7.81%
Apr-04-25 07:00AM	NextCure to Present at 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
04:05PM	Loading…
Mar-06-25 04:05PM	NextCure Provides Business Update and Reports Full Year 2024 Financial Results (GlobeNewswire) +5.20%
Jan-10-25 08:05AM	NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers (GlobeNewswire) -6.11%
Dec-10-24 08:05AM	NextCure Announces Acceptance of IND Application for LNCB74 (GlobeNewswire)
Nov-26-24 07:00AM	NextCure to Participate in the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-19-24 08:05AM	Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta (GlobeNewswire)
Nov-08-24 06:18AM	NextCure goes all in on B7-H4, stopping other programs to challenge Big Pharma in ADC space (FierceBiotech.com)
Nov-07-24 04:05PM	NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-05-24 04:05PM	NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Oct-04-24 09:05AM	NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-16-24 08:05AM	NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024 (GlobeNewswire)
Aug-01-24 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-20-24 04:10PM	NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference (GlobeNewswire) +13.64% +8.00%
May-30-24 04:05PM	NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024 (GlobeNewswire)
May-02-24 09:57PM	NXTC Stock Earnings: NextCure Misses EPS for Q1 2024 (InvestorPlace) +8.76%
04:05PM	NextCure Provides Business Update and Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:05PM	NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024 (GlobeNewswire) -5.88% -10.42%
Apr-08-24 07:00AM	NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024 (GlobeNewswire) -5.96%
Apr-04-24 07:05AM	NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board (GlobeNewswire) -10.00%
Apr-02-24 07:00AM	NextCure to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +7.79%
Mar-23-24 06:00AM	Wall Streets Favorite Penny Stocks? 7 Names That Could Make You Filthy Rich (InvestorPlace)
Mar-21-24 10:54PM	NXTC Stock Earnings: NextCure Beats EPS for Q4 2023 (InvestorPlace) +19.15% +13.10%
11:22AM	NextCure to lay off 37% of staff, dial back research plans (BioPharma Dive)
08:55AM	NextCure Provides Business Update and Reports Full Year 2023 Financial Results (GlobeNewswire)
Mar-05-24 08:05AM	NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances (GlobeNewswire)
Jan-18-24 04:05PM	NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders (GlobeNewswire)
Dec-25-23 09:55AM	Here's Why NextCure, Inc. (NXTC) Looks Ripe for Bottom Fishing (Zacks)
Dec-21-23 07:05AM	NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury (GlobeNewswire)
Dec-15-23 11:23AM	NextCure (NXTC) Down on Shelving Plans to Develop Candidate (Zacks) -5.13%
Dec-14-23 09:14AM	NextCure jettisons monoclonal antibody to focus on ADC aimed at same target (FierceBiotech.com) -19.31%
06:45AM	NextCure Provides Year-End Clinical Pipeline Updates (GlobeNewswire)
Nov-20-23 07:00AM	NextCure to Present at the 35th Annual Piper Sandler Healthcare Conference (GlobeNewswire)
Nov-15-23 04:05PM	NextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML (GlobeNewswire) +5.93% -6.40%
Nov-07-23 12:00PM	All You Need to Know About NextCure, Inc. (NXTC) Rating Upgrade to Buy (Zacks)
Nov-02-23 06:07PM	NextCure Inc (NXTC) Reports Q3 2023 Financial Results (GuruFocus.com) +9.35%
04:05PM	NextCure Provides Business Update and Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-17-23 08:05AM	Preclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI) (GlobeNewswire)
Sep-26-23 04:05PM	NextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimers Disease (GlobeNewswire)
Sep-12-23 08:05AM	A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC (GlobeNewswire)
Sep-07-23 04:05PM	NextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen (GlobeNewswire)
Sep-05-23 04:05PM	Preclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease (GlobeNewswire)
Aug-31-23 07:00AM	NextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-03-23 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jun-21-23 04:05PM	NextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting (GlobeNewswire)
May-11-23 01:58PM	Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? (Simply Wall St.)
May-09-23 07:00AM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire) +7.41%
May-04-23 04:05PM	NextCure Provides Business Update and Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-11-23 07:00AM	NextCure to Present at 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-02-23 04:05PM	NextCure Provides Business Update and Reports Full Year 2022 Financial Results (GlobeNewswire)
Feb-07-23 07:00AM	NextCure to Present at SVB Securities Global Biopharma Conference (GlobeNewswire)
Dec-02-22 10:59AM	Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-22-22 08:00AM	NextCure to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-16-22 08:09AM	NextCure, LegoChem Biosciences Ink Collaborative Pact For Antibody Drug Conjugates (Benzinga) -6.02%
Nov-15-22 04:30PM	NextCure and LegoChem Biosciences Enter into Collaboration and Co-Development Agreement to Develop Antibody Drug Conjugates (GlobeNewswire)
Nov-07-22 08:05AM	NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) -13.64%
Nov-03-22 04:15PM	NextCure Provides Update and Reports Third Quarter 2022 Financial Results (GlobeNewswire) -21.12%
09:15AM	NextCure to Present Trial in Progress Poster for NC525 at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-27-22 04:05PM	NextCure Appoints Dr. Lisa M. Coussens to Scientific Advisory Board (GlobeNewswire)
Oct-05-22 12:00PM	NextCure, Inc. (NXTC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
08:15AM	NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Oct-04-22 04:05PM	NextCure Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors (GlobeNewswire) +9.42%
Sep-22-22 08:00AM	NextCure to Present at the Ladenburg Thalmann Healthcare Conference (GlobeNewswire) -12.64%
Aug-22-22 06:23AM	With 37% ownership, NextCure, Inc. (NASDAQ:NXTC) has piqued the interest of institutional investors (Simply Wall St.) -5.45%
Aug-04-22 04:05PM	NextCure Provides Business Update and Reports Second Quarter 2022 Financial Results (GlobeNewswire) +6.32%
Jul-06-22 08:00AM	NextCure Announces Development of a Highly Specific Immunohistochemical Diagnostic for Siglec-15-positive Tumors as reported in Laboratory Investigation (GlobeNewswire)
Jun-27-22 08:00AM	NextCure Presented NC410 Data at the Extracellular Matrix (ECM) Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM (GlobeNewswire)
Jun-25-22 10:26AM	We're Hopeful That NextCure (NASDAQ:NXTC) Will Use Its Cash Wisely (Simply Wall St.)
Jun-22-22 08:00AM	Dr. Brahm Segal appointed to NextCure Scientific Advisory Board; NextCure and Roswell Park Shared Nonclinical Data on the Impact of NC410 Blockade on Neutrophil-mediated T Cell Suppression at the 24th Translational Research Cancer Centers Consortium Annual Meeting (GlobeNewswire)
Jun-08-22 08:00AM	NextCure to Present at the JMP Securities Life Sciences Conference (GlobeNewswire)
May-11-22 08:17AM	NextCure, Inc.'s (NASDAQ:NXTC) Intrinsic Value Is Potentially 34% Above Its Share Price (Simply Wall St.)
May-05-22 04:05PM	NextCure Provides Business Update and Reports First Quarter 2022 Financial Results (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Simcere Zaiming, Inc.	Former 10% Owner	Aug 10 '26	Sale	6.16	30,000	184,800	308,636	Aug 12 11:35 AM
ADAR1 Capital Management, LLC	10% Owner	Jul 30 '26	Buy	4.93	292,850	1,444,746	686,116	Aug 03 05:53 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 31 '26	Buy	4.94	36,303	179,375	722,419	Aug 03 05:53 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 27 '26	Buy	5.00	7,798	38,985	383,456	Jul 29 06:18 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 28 '26	Buy	4.95	6,400	31,677	389,856	Jul 29 06:18 PM
ADAR1 Capital Management, LLC	10% Owner	Jul 29 '26	Buy	5.00	3,410	17,050	393,266	Jul 29 06:18 PM

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Co-FounderMr. Michael S. Richman MSBA

Chief Operating OfficerDr. Timothy Mayer Ph.D.

Ph.D.Dr. Udayan Guha M.D.

Ph.D.Dr. Lieping Chen M.D.

Chief Financial OfficerMr. Steven P. Cobourn CPA

Peers: OLMA CELC ARVN RLAY STRO INCY ACRV BDTX ZYME PFE

| Held by: VTI VXF IWC DFAS DFMC AVSC DXUV DCOR DFAC

Index	-
Market Cap	87.13M
Enterprise Value	-5.72M
Income	45.55M
Sales	0.65M
Book/sh	17.81
Cash/sh	17.48
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Jul 29, 2021

P/E	2.10
Forward P/E	-
PEG	-
P/S	134.05
P/B	0.92
P/C	0.94
P/FCF	3.26
EV/EBITDA	-
EV/Sales	-8.80
Quick Ratio	27.26
Current Ratio	27.26
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	7.81
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	54.34% 24.69%
Sales past 3/5Y	- -
EPS Y/Y TTM	206.57%
Sales Y/Y TTM	-15.11%
EPS Q/Q	535.05%
Sales Q/Q	-100.00%
Earnings	-
EPS/Sales Surpr.	268.75% 217.84%

Insider Own	23.23%
Insider Trans	32.47%
Inst Own	59.75%
Inst Trans	-28.80%
ROA	61.12%
ROE	64.86%
ROIC	48.20%
Gross Margin	93.34%
Oper. Margin	-3409.13%
Profit Margin	7051.24%
SMA20	-2.28%
SMA50	-2.60%
SMA200	29.95%
Trades

Shs Outstand	5.31M
Shs Float	4.08M
Short Float	1.21%
Short Ratio	3.20
Short Interest	0.05M
52W High	17.57 -6.68%
52W Low	3.67 346.85%
Volatility	1.87% 1.96%
ATR (14)	0.34
RSI (14)	43.06
Beta	-0.74
Rel Volume	0.00
Avg Volume	15.41K
Volume	0

Perf Week	-2.24%
Perf Month	-2.73%
Perf Quarter	0.55%
Perf Half Y	92.94%
Perf YTD	198.79%
Perf Year	265.48%
Perf 3Y	-39.35%
Perf 5Y	-87.37%
Perf 10Y	-
Recom	2.50
Target Price	8.00
Prev Close	16.40
Price	16.40
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-09-25	Downgrade	H.C. Wainwright	Buy → Neutral
May-15-24	Downgrade	JP Morgan	Overweight → Neutral
Feb-07-24	Downgrade	Jefferies	Buy → Hold	$7 → $1.50
Apr-17-23	Initiated	H.C. Wainwright	Buy	$18
Apr-10-23	Initiated	Wedbush	Outperform	$17
Dec-09-22	Initiated	JP Morgan	Overweight	$21
Feb-22-22	Initiated	JMP Securities	Mkt Outperform	$32
Aug-23-21	Initiated	Jefferies	Buy	$20
Aug-23-21	Initiated	Evercore ISI	Outperform	$40
Aug-23-21	Initiated	Cowen	Outperform

Jul-21-26 02:53PM	Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-24-26 02:15PM	VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development (Exec Edge)
Jun-22-26 11:40AM	Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing (Exec Edge)
Jun-09-26 01:19PM	Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders? (PR Newswire)
Jun-01-26 12:26PM	RLYB Stock Hits 2-Year Highs After Unveiling Merger With Avenzo How Much Of The New Company Will Rallybio Shareholders Own? (Stocktwits) +16.67%
11:03AM	Loading…
11:03AM	RallyBio tries again for reverse merger, this time with Avenzo (BioPharma Dive)
08:00AM	Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement (Business Wire)
Apr-09-26 03:29PM	Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders? (PR Newswire)
Apr-06-26 02:38PM	Are EWCZ, STEL, RLYB, CTRA Obtaining Fair Deals for their Shareholders? (PR Newswire)
Mar-06-26 11:15AM	Are RLYB, VRME, AES Obtaining Fair Deals for their Shareholders? (PR Newswire)
Mar-03-26 07:20AM	Rallybio to acquire Candid Therapeutics (Pharmaceutical Business Review)
Mar-02-26 03:56PM	Are KW, AES, RLYB Obtaining Fair Deals for their Shareholders? (PR Newswire) +45.49%
10:51AM	Tiny Biotech Rallybio Stock Surges As $500 Million-Backed Merger Fuels Investor Optimism (Benzinga)
08:00AM	Rallybio Corporation and Candid Therapeutics Announce Merger Agreement (Business Wire)
06:05AM	Candid, in a reverse merger with RallyBio, to go public (BioPharma Dive)
10:46AM	Loading…
Feb-17-26 10:46AM	Rallybio Shares Successful Early-Stage Results for Rare Disease Drug; New Trial Set for Late 2026 (Benzinga) -10.17%
08:00AM	Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement (Business Wire)
Feb-04-26 10:05AM	Stock Splits Matter: Whats Coming Up This Month? (24/7 Wall St.) -8.12%
Feb-03-26 04:05PM	Rallybio Announces Reverse Stock Split of Common Stock (Business Wire)
Nov-06-25 08:00AM	Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Sep-25-25 08:00AM	Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study (Business Wire)
Sep-03-25 08:00AM	Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program (Business Wire)
Aug-07-25 08:00AM	Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Aug-05-25 06:30AM	Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-21-25 12:14AM	Recursion Pharmaceuticals Acquires Full Rights to REV102, Potential Oral Therapy for Rare Bone Disorder Hypophosphatasia (Insider Monkey) +7.51%
Jul-09-25 11:56AM	RXRX Stock Up on Acquiring Full Rights to the Hypophosphatasia Program (Zacks) -12.71%
08:16AM	Rallybio to sell interest in REV102 to Recursion Pharmaceuticals for up to $25M (TipRanks)
07:18AM	Rallybio sells REV102 programme to Recursion for up to $25m (Pharmaceutical Business Review)
Jul-08-25 01:28PM	Here's Why Shares in Recursion Pharmaceuticals Surged Today (Motley Fool) +50.24%
08:00AM	Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia (GlobeNewswire)
08:00AM	Loading…
08:00AM	Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals (Business Wire)
Jul-07-25 09:00AM	ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors (Business Wire)
Jun-12-25 08:00AM	Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study (Business Wire) -7.30%
May-08-25 08:00AM	Rallybio Reports First Quarter 2025 Financial Results and Provides Business Updates (Business Wire)
Apr-29-25 08:00AM	Rallybio to Present at the 2025 Citizens JMP Life Sciences Conference (Business Wire)
Apr-09-25 10:58AM	RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks (Zacks)
07:21AM	Rallybio drops drug for rare maternal disorder following Phase II fail (Clinical Trials Arena)
Apr-08-25 08:00AM	Rallybio to Discontinue Development of RLYB212 for Prevention of FNAIT (Business Wire) -41.16%
05:27AM	Rallybio discontinues lead drug for rare maternal disorder (BioPharma Dive)
Mar-13-25 08:00AM	Rallybio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates (Business Wire)
Feb-25-25 08:00AM	Rallybio to Present at the TD Cowen 45th Annual Health Care Conference (Business Wire) -6.30%
Feb-12-25 05:29AM	Rallybio doses first subject in Phase II trial of treatment for FNAIT in Europe (Clinical Trials Arena)
Feb-11-25 08:00AM	Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial (Business Wire)
Jan-10-25 08:00AM	Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025 (Business Wire) -5.63%
Dec-10-24 08:00AM	Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting (Business Wire)
Dec-06-24 06:48AM	Rallybio price target lowered to $7 from $8 at JMP Securities (TipRanks)
Dec-02-24 08:00AM	Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 (Business Wire)
Nov-27-24 08:00AM	Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women (Business Wire)
Nov-26-24 08:00AM	Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference (Business Wire)
Nov-25-24 08:00AM	Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor (Business Wire)
Nov-22-24 07:01AM	Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women (Clinical Trials Arena)
Nov-21-24 08:00AM	Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 (Business Wire)
Nov-07-24 08:00AM	Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Nov-05-24 02:59AM	Two former Alexion leaders fight through a tough market to maintain a rare disease biotech (Pharma Voice)
Oct-29-24 08:00AM	Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT (Business Wire)
Sep-30-24 08:00AM	Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting (Business Wire) +5.88%
Sep-23-24 08:00AM	Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting (Business Wire)
Sep-10-24 08:00AM	Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit (Business Wire)
Sep-09-24 05:15PM	Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree (Business Wire)
Aug-29-24 08:00AM	Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis (Business Wire)
Aug-27-24 08:00AM	Rallybio to Present at Upcoming Investor Conferences (Business Wire) +8.77%
Aug-14-24 12:00PM	Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Aug-08-24 08:00AM	Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
Jul-09-24 08:00AM	Rallybio to Present at the 2024 Jones Healthcare Seaside Summit (Business Wire)
Jun-17-24 08:00AM	Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations (Business Wire) -6.15%
May-31-24 07:00AM	3 Sorry Biotech Stocks to Sell in May While You Still Can (InvestorPlace) +5.03%
May-10-24 06:30AM	3 Biotech Stocks to Sell in May Before They Crash & Burn (InvestorPlace)
May-09-24 01:54PM	RLYB Stock Earnings: Rallybio Beats EPS for Q1 2024 (InvestorPlace)
10:14AM	Rallybio reins in preclinical R&D, while Monopar pivots to radiopharma to eke out cash (FierceBiotech.com)
08:00AM	Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates (Business Wire)
May-07-24 08:00AM	Rallybio to Present at the 2024 Citizens JMP Life Sciences Conference (Business Wire)
Apr-17-24 04:01PM	FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting (Business Wire) -5.11%
Apr-12-24 10:23AM	RallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up (Zacks) -26.17%
Apr-11-24 07:43AM	Why Is Rallybio (RLYB) Stock Up 93% Today? (InvestorPlace) +82.82%
Apr-10-24 04:01PM	Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) (Business Wire)
01:01PM	J&J, Rallybio partner on drug development for rare fetal condition (BioPharma Dive)
Apr-01-24 10:05AM	Rallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual Meeting (Business Wire)
Mar-12-24 08:00AM	Rallybio Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) -8.70%
Feb-26-24 08:00AM	Rallybio to Present at the TD Cowen 44th Annual Health Care Conference (Business Wire) +5.88%
Feb-06-24 09:46AM	Rallybio, with financial fuel levels falling, loses 45% of workforce to extend cash runway into 2026 (FierceBiotech.com) +24.00%
08:00AM	Rallybio Announces Portfolio Prioritization and Provides Corporate Update (Business Wire)
Jan-04-24 08:00AM	Rallybio Highlights Portfolio Advances and Outlines Expected Milestones in 2024 (Business Wire)
Dec-20-23 08:00AM	Rallybio Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 (Business Wire) -5.50%
Dec-09-23 12:00PM	Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting (Business Wire)
Nov-28-23 07:00AM	Rallybio Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212, an Anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire) -10.00%
Nov-09-23 08:00AM	Rallybio Reports Third Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Nov-08-23 08:00AM	Rallybio to Present at Upcoming Investor Conferences in November (Business Wire) -12.79%
Nov-02-23 09:15AM	Rallybio Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting (Business Wire)
Oct-03-23 08:00AM	Rallybio to Present at the JonesTrading 2023 Healthcare Summit (Business Wire) +10.14%
Sep-03-23 12:00PM	Rallybio Presents Phase 1 Single Ascending Dose Data for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5 (Business Wire)
Aug-31-23 08:00AM	Rallybio to Present at Upcoming Investor Conferences in September (Business Wire)
Aug-08-23 08:00AM	Rallybio Reports Second Quarter 2023 Financial Results and Provides Business Updates (Business Wire)
Aug-02-23 08:00AM	Rallybio to Present at the 2023 Wedbush PacGrow Healthcare Conference (Business Wire)
Jul-11-23 08:00AM	Rallybio Announces Acceptance of Abstract for RLYB116 at the 29th International Complement Workshop (ICW) (Business Wire)
Jun-29-23 07:00AM	Rallybio Announces Succession Plan; Appoints Stephen Uden, M.D., as Chief Executive Officer, Effective August 1, 2023 (Business Wire) -5.57%
Jun-24-23 03:30PM	Rallybio Announces Proof-of-Concept Results and Development Updates for RLYB212, a Novel Monoclonal anti-HPA-1a Antibody to Prevent Fetal and Neonatal Alloimmune Thrombocytopenia (Business Wire)
Jun-09-23 09:15AM	Rallybio to Present Data from the RLYB212 Phase 1b Proof-of-Concept Study at the 31st Congress of the International Society on Thrombosis and Haemostasis (Business Wire)
Jun-01-23 08:00AM	Rallybio to Present at the Jefferies Healthcare Conference (Business Wire) +6.01%
May-29-23 09:55AM	Wall Street Analysts Believe Rallybio Corporation (RLYB) Could Rally 202.36%: Here's is How to Trade (Zacks)
May-12-23 09:55AM	Does Rallybio Corporation (RLYB) Have the Potential to Rally 290.63% as Wall Street Analysts Expect? (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Soteropoulos Paula	Director	Oct 16 '26	Option Exercise	2.38	3,562	8,478	6,544	Oct 20 05:32 PM
Boudreau Helen M	Director	Oct 16 '26	Option Exercise	15.28	2,062	31,507	8,604	Oct 20 05:29 PM
Hopfner Robert Lorne	Director	Oct 12 '26	Option Exercise	7.41	14,820	109,875	14,820	Oct 14 04:34 PM
Lieber Jonathan I	Chief Financial Officer	Oct 09 '26	Option Exercise	6.08	3,910	23,773	13,650	Oct 13 04:50 PM
Uden Stephen	Chief Executive Officer	Oct 06 '26	Option Exercise	6.08	22,456	136,532	115,620	Oct 08 05:04 PM
Lieber Jonathan I	Chief Financial Officer	Sep 29 '26	Option Exercise	6.08	5,000	30,400	9,740	Oct 01 05:32 PM
Liu Hui	Director	Sep 24 '26	Option Exercise	6.06	12,044	72,941	12,044	Sep 28 09:00 PM
Chung Wendy	Director	Sep 16 '26	Option Exercise	2.38	3,562	8,478	3,562	Sep 18 05:42 PM
Boudreau Helen M	Director	Jul 06 '26	Option Exercise	2.38	3,562	8,478	6,542	Jul 10 04:14 PM
ADAR1 Capital Management, LLC	10% Owner	May 19 '26	Buy	13.98	10,200	142,582	926,352	May 20 08:45 PM
ADAR1 Capital Management, LLC	10% Owner	May 18 '26	Buy	13.98	6,009	83,981	916,152	May 20 08:45 PM
ADAR1 Capital Management, LLC	10% Owner	May 13 '26	Buy	13.99	79,259	1,108,807	909,843	May 15 08:49 PM
ADAR1 Capital Management, LLC	10% Owner	May 15 '26	Buy	13.90	300	4,170	910,143	May 15 08:49 PM
ADAR1 Capital Management, LLC	10% Owner	May 11 '26	Buy	14.00	50,000	699,992	829,784	May 13 09:22 PM
ADAR1 Capital Management, LLC	10% Owner	May 12 '26	Buy	13.83	800	11,063	830,584	May 13 09:22 PM
ADAR1 Capital Management, LLC	10% Owner	May 04 '26	Buy	13.97	120,804	1,687,409	744,683	May 06 09:32 PM
ADAR1 Capital Management, LLC	10% Owner	May 05 '26	Buy	14.00	35,101	491,260	779,784	May 06 09:32 PM
Lieber Jonathan I	Chief Financial Officer	Feb 23 '26	Sale	5.06	789	3,992	4,115	Feb 23 06:21 PM

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.

Co-Founder & ChairmanDr. Martin W. MacKay Ph.D.

MBBSDr. Stephen Uden M.D.

KROS Keros Therapeutics Inc daily Stock Chart

Peers: SRRK CAPR EWTX TRDA SLDB DYN SRPT WVE GERN IRON

| Held by: VTI IWM VXF IWN DFSV IBB VTWO SMLF BSVO SCHA

Index	RUT
Market Cap	225.04M
Enterprise Value	-16.85M
Income	-83.16M
Sales	15.01M
Book/sh	13.23
Cash/sh	12.99
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	78
IPO	Apr 08, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	14.99
P/B	0.86
P/C	0.87
P/FCF	-
EV/EBITDA	-
EV/Sales	-1.12
Quick Ratio	21.96
Current Ratio	21.96
Debt/Eq	0.06
LT Debt/Eq	0.05
Option/Short	Yes / Yes

EPS (ttm)	-3.70
EPS next Y	-6.24
EPS next Q	-0.94
EPS this Y	-340.77%
EPS next Y	-12.61%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-1143.58%
Sales Y/Y TTM	-93.55%
EPS Q/Q	-91.85%
Sales Q/Q	-100.00%
Earnings	Aug 03 AMC
EPS/Sales Surpr.	-8.21% -100.00%

Insider Own	8.45%
Insider Trans	-0.84%
Inst Own	92.13%
Inst Trans	-0.43%
ROA	-15.92%
ROE	-17.16%
ROIC	-30.19%
Gross Margin	89.34%
Oper. Margin	-675.27%
Profit Margin	-553.88%
SMA20	0.41%
SMA50	1.44%
SMA200	-7.68%
Trades

Shs Outstand	19.83M
Shs Float	18.15M
Short Float	6.33%
Short Ratio	6.07
Short Interest	1.15M
52W High	22.55 -49.67%
52W Low	9.69 17.13%
Volatility	4.54% 4.55%
ATR (14)	0.50
RSI (14)	51.49
Beta	1.13
Rel Volume	0.00
Avg Volume	189.45K
Volume	0

Perf Week	2.25%
Perf Month	-2.41%
Perf Quarter	12.82%
Perf Half Y	-1.82%
Perf YTD	-44.25%
Perf Year	-27.06%
Perf 3Y	-59.95%
Perf 5Y	-70.76%
Perf 10Y	-
Recom	1.86
Target Price	19.83
Prev Close	11.35
Price	11.35
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Initiated	Wells Fargo	Overweight	$26
Jun-10-25	Downgrade	BofA Securities	Buy → Neutral	$18
Jan-21-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-17-25	Downgrade	Wedbush	Outperform → Neutral	$15
Dec-16-24	Reiterated	Oppenheimer	Outperform	$102 → $63
Dec-16-24	Downgrade	Guggenheim	Buy → Neutral
Dec-13-24	Reiterated	H.C. Wainwright	Buy	$100 → $47
Dec-12-24	Downgrade	William Blair	Outperform → Mkt Perform
Dec-12-24	Downgrade	TD Cowen	Buy → Hold
Dec-12-24	Downgrade	BTIG Research	Buy → Neutral
Nov-05-24	Initiated	Jefferies	Buy
Oct-24-24	Initiated	Cantor Fitzgerald	Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-23-24	Initiated	Guggenheim	Buy	$96
Jun-25-24	Initiated	Oppenheimer	Outperform	$102
Feb-21-24	Initiated	William Blair	Outperform
Dec-08-23	Initiated	Wells Fargo	Overweight	$60
Jul-31-23	Initiated	Wedbush	Outperform	$86
Jul-26-23	Initiated	BofA Securities	Buy	$65
Feb-14-23	Initiated	Cowen	Outperform

Show Previous Ratings

Oct-20-26 08:59AM	A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday (PR Newswire)
Sep-29-26 08:00AM	Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda (GlobeNewswire)
Sep-28-26 08:00AM	Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD (GlobeNewswire)
Sep-08-26 04:01PM	Keros Therapeutics Announces $5 Million Share Repurchase Authorization (GlobeNewswire)
Aug-03-26 04:01PM	Keros Therapeutics Reports Second Quarter 2026 Financial Results (GlobeNewswire)
04:01PM	Loading…
Jul-30-26 04:01PM	Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda (GlobeNewswire)
Jun-25-26 04:01PM	Keros Therapeutics Appoints Anne Prener to its Board of Directors (GlobeNewswire) +5.57%
Jun-01-26 04:01PM	Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-14-26 08:00AM	Keros Therapeutics Reports Recent First Quarter 2026 Financial Results (GlobeNewswire) -8.34%
Mar-09-26 08:00AM	Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
08:00AM	Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS (GlobeNewswire)
Mar-06-26 11:57AM	Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? (Zacks)
Mar-05-26 12:53PM	Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? (Zacks) -14.96%
Mar-04-26 05:10PM	Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
12:35PM	Loading…
Feb-28-26 12:35PM	Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference (MarketBeat)
Feb-26-26 04:01PM	Keros Therapeutics Appoints Charles Newton to its Board of Directors (GlobeNewswire) -5.59%
Feb-18-26 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-03-26 11:39AM	Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results? (Zacks)
Jan-27-26 10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-26-26 09:15AM	Is KROS' KER-065 the Next Breakthrough in DMD Space? (Zacks)
Jan-23-26 07:18AM	JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
Jan-21-26 08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
Jan-19-26 12:53PM	Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease (Zacks)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks)
09:08AM	Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? (Zacks)
Jan-15-26 10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
09:14AM	Loading…
09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks)
Jan-14-26 10:54AM	TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA (Zacks)
10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
Jan-13-26 01:00PM	BEAM Outlines Key Strategic & Pipeline Goals for 2026, Stock Rises (Zacks)
Jan-12-26 09:32AM	INSM Stock Jumps on 2025 Preliminary Sales, 2026 Goals Announced (Zacks)
Jan-08-26 12:33PM	GSK's Chronic Hepatitis B Drug Meets Goals in Two Late-Stage Studies (Zacks)
Jan-02-26 12:41PM	This Health Name Gains Over 400% In 2025. A Gold Stock Is Right Behind It. (Investor's Business Daily) -8.94%
04:32AM	Zacks.com featured highlights include AES, BorgWarner, Enersys, PG&E and Keros Therapeutics (Zacks)
Dec-31-25 07:33AM	5 Low Price-to-Book Stocks to Buy as 2025 Comes to a Close (Zacks)
Dec-30-25 11:40AM	KROS or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Dec-22-25 12:00PM	Keros Therapeutics (KROS) Upgraded to Strong Buy: Here's Why (Zacks) +5.33%
09:55AM	Here's Why Keros Therapeutics (KROS) Could be Great Choice for a Bottom Fisher (Zacks)
Dec-16-25 09:23AM	5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026 (Zacks)
04:02AM	Zacks.com featured highlights include StoneCo, General Motors, Enersys, Deutsche, Keros (Zacks)
Dec-15-25 09:14AM	Buy These 5 Best Value Stocks to Boost Your Portfolio in December (Zacks)
Dec-12-25 12:00PM	What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? (Zacks)
11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
Nov-28-25 09:53AM	Buy These 5 Best Value Stocks to Make the Most of P/B Ratio (Zacks)
Nov-26-25 11:40AM	KROS or NVZMY: Which Is the Better Value Stock Right Now? (Zacks)
09:55AM	How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% (Zacks)
Nov-20-25 04:01PM	Keros Therapeutics Announces Final Results of Tender Offer (GlobeNewswire)
Nov-19-25 06:00AM	Keros Therapeutics Announces Preliminary Results of Tender Offer (GlobeNewswire)
Nov-13-25 07:34AM	5 Undervalued Stocks That Are Poised for Growth in November (Zacks)
Nov-10-25 11:40AM	KROS vs. ARGX: Which Stock Is the Better Value Option? (Zacks) +5.19%
09:55AM	Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? (Zacks)
Nov-05-25 05:40PM	Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Keros Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-21-25 09:43AM	Keros Therapeutics (KROS) Moves 9.8% Higher: Will This Strength Last? (Zacks)
Oct-20-25 06:00AM	Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares (GlobeNewswire) +9.83%
Oct-15-25 06:30AM	Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital (GlobeNewswire)
Sep-08-25 08:00AM	Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting (GlobeNewswire)
Aug-28-25 04:01PM	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences (GlobeNewswire)
Aug-21-25 08:30AM	ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment (PR Newswire) +6.61%
06:56AM	Keros gains FDA orphan drug status for DMD treatment KER-065 (Pharmaceutical Technology)
Aug-20-25 09:48AM	Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-06-25 05:45PM	Keros Therapeutics, Inc. (KROS) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -7.29%
04:15PM	Keros to Exclusively Prioritize the Clinical Advancement of KER-065 (GlobeNewswire)
04:01PM	Keros Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-28-25 11:40AM	KROS vs. EXAS: Which Stock Should Value Investors Buy Now? (Zacks)
Jul-23-25 10:54AM	Will Reblozyl Enable BMY to Offset the Impact of Generic Competition? (Zacks) +5.10%
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks)
10:39AM	FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo (Zacks)
Jul-17-25 08:00AM	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept (GlobeNewswire)
Jul-10-25 12:10PM	KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up (Zacks)
11:09AM	RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data (Zacks)
Jun-11-25 09:40AM	McDonalds downgraded on GLP-1 drug worries: Wall Streets top analyst calls (TipRanks)
Jun-10-25 02:37PM	Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst (Benzinga)
Jun-09-25 03:12PM	ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal (PR Newswire) -6.32%
06:55AM	Keros Announces Return of $375 Million in Excess Capital to Stockholders (GlobeNewswire)
Jun-06-25 04:01PM	Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-30-25 06:36AM	Keros lays off nearly half its staff; Astellas buys into a China biotechs ADC (BioPharma Dive)
May-29-25 11:24PM	Keros Therapeutics, Inc. (KROS) Halts PAH Drug Development After Safety Concerns in TROPOS Trial (Insider Monkey)
12:54PM	Keros Therapeutics Stops PAH Drug Development, Shrinks Workforce By 45% (Benzinga)
06:55AM	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring (GlobeNewswire)
May-27-25 01:45PM	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees (GlobeNewswire)
May-21-25 08:00AM	ADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
May-19-25 08:00AM	Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value (GlobeNewswire)
May-12-25 12:11PM	ADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna Seth (PR Newswire)
08:00AM	Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference (GlobeNewswire)
May-08-25 05:31PM	Keros Reinforces Commitment to Maximizing Stockholder Value (GlobeNewswire)
02:10PM	ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders (PR Newswire)
May-06-25 07:10PM	Keros Therapeutics, Inc. (KROS) Q1 Earnings and Revenues Beat Estimates (Zacks) -5.46%
04:01PM	Keros Therapeutics Reports Recent First Quarter 2025 Financial Results (GlobeNewswire)
May-05-25 05:10PM	Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-02-25 08:40AM	Implied Volatility Surging for Keros Therapeutics Stock Options (Zacks)
Apr-11-25 02:13PM	Keros Therapeutics: Strategic Alternatives Could Bring About Value Creation (Seeking Alpha)
12:05PM	Prada to acquire Versace, CarMax reports mixed Q4 results: Morning Buzz (TipRanks)
11:57AM	KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% (Zacks)
Apr-10-25 12:58PM	Keros Therapeutics considers sale amid investor pressure (Pharmaceutical Technology) +18.49%
06:00AM	Keros Therapeutics Announces Review of Strategic Alternatives (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tanini Annita	Corp. Controller & VP, Finance	Aug 18 '26	Sale	10.29	1,224	12,595	45,144	Aug 20 04:10 PM
Lerner Lorena Raquel	Chief Scientific Officer	Aug 18 '26	Sale	10.29	3,568	36,715	27,559	Aug 20 04:10 PM
Cho Esther	Chief Legal Officer	Aug 18 '26	Sale	10.29	4,485	46,151	35,770	Aug 20 04:10 PM
Newton Charles W.	Director	Aug 18 '26	Sale	10.30	551	5,675	12,114	Aug 20 04:10 PM
BIENAIME JEAN JACQUES	Director	Aug 17 '26	Buy	10.27	1,000	10,270	19,592	Aug 19 04:10 PM
Newton Charles W.	Director	Aug 18 '26	Proposed Sale	10.38	551	5,719		Aug 18 04:11 PM
BIENAIME JEAN JACQUES	Director	Jul 15 '26	Buy	10.61	1,000	10,610	18,592	Jul 17 04:10 PM
BIENAIME JEAN JACQUES	Director	Jun 15 '26	Buy	10.19	1,000	10,190	17,592	Jun 17 04:55 PM
Newton Charles W.	Director	Jun 11 '26	Sale	10.04	550	5,522	12,665	Jun 15 04:15 PM
Newton Charles W.	Director	Jun 11 '26	Proposed Sale	9.95	550	5,472		Jun 11 04:15 PM
Farzan Nima	Director	Jun 04 '26	Sale	10.73	2,625	28,166	9,767	Jun 08 04:37 PM
Knowles Julius	Director	Jun 04 '26	Sale	10.73	2,625	28,166	10,958	Jun 08 04:36 PM
Seth Alpna	Director	Jun 04 '26	Sale	10.72	2,625	28,140	9,767	Jun 05 04:15 PM
Farzan Nima	Director	Jun 04 '26	Proposed Sale	10.68	2,625	28,035		Jun 04 04:11 PM
Knowles Julius	Director	Jun 04 '26	Proposed Sale	10.68	2,625	28,035		Jun 04 04:09 PM
Seth Alpna	Director	Jun 04 '26	Proposed Sale	10.68	2,625	28,035		Jun 04 04:07 PM
BIENAIME JEAN JACQUES	Director	May 15 '26	Buy	10.58	1,000	10,580	9,450	May 19 04:15 PM
BIENAIME JEAN JACQUES	Director	Apr 15 '26	Buy	11.70	1,000	11,700	8,450	Apr 17 04:15 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Apr 02 '26	Option Exercise	0.30	55,000	16,500	440,708	Apr 06 04:15 PM
OrbiMed Genesis Master Fund, L	Shareholder	Mar 31 '26	Proposed Sale	11.04	45,057	497,429		Mar 31 09:57 PM
BIENAIME JEAN JACQUES	Director	Mar 09 '26	Buy	11.21	2,000	22,420	7,450	Mar 11 04:33 PM
Seehra Jasbir	CHIEF EXECUTIVE OFFICER	Feb 19 '26	Sale	16.17	7,015	113,433	385,708	Feb 20 04:15 PM
Lerner Lorena Raquel	Chief Science Officer	Feb 18 '26	Sale	16.35	3,873	63,324	31,127	Feb 20 04:15 PM
Cho Esther	SVP, General Counsel	Feb 18 '26	Sale	16.35	4,745	77,581	39,755	Feb 20 04:15 PM
Regnante Keith	CHIEF FINANCIAL OFFICER	Feb 18 '26	Sale	16.35	4,739	77,483	39,261	Feb 20 04:15 PM

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

PresidentDr. Jasbir S. Seehra Ph.D.

Chief Legal Officer & SecretaryMs. Esther Cho J.D.

VP of FinanceMs. Annita Tanini

Head of Investor RelationsJustin Frantz

Chief Scientific OfficerDr. Lorena Lerner Ph.D.

TENX

Tenax Therapeutics Inc

INM

InMed Pharmaceuticals Inc

NXTC

Nextcure Inc

RLYB

Rallybio Corp

KROS

Keros Therapeutics Inc

Upgrade your Finviz experience